CD200 and neoplasm: A further 7 days after treatment, larger UWBCC1POS tumors after CD200-blocking antibody treatment demonstrated reduced cellularity (P < 0.05) from increased immune cell infiltrate (P < 0.05) and tumor necrosis (P < 0.05) (Figure 7D).